RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Bio-Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties.
A Bio-Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤(NK)细胞疗法主要采用嵌合抗原受体NK细胞(CAR-NK),已开发并应用于中晚期肿瘤患者的临床治疗。然而,由于肿瘤细胞表面抗原表达不足,NK细胞疗法疗效有限。本文介绍一种通用的“照亮肿瘤并均一化抗原特征”(ITHAP)策略:利用纳米医学在肿瘤细胞表面实现稳定、可控的抗原表达,从而显著提高肿瘤细胞的免疫可识别性。ITHAP策略采用生物脂质体(Pt@PL-IgG),由交错混合的血小板膜和脂质体组成,并携带可被NK细胞识别的靶抗原(IgG抗体)及顺铂前药。研究证实,Pt@PL-IgG借助血小板膜的自主驱动靶向肿瘤细胞,并利用膜融合特性将IgG植入肿瘤细胞。研究还发现,Pt-DNA复合物与NK细胞诱导的细胞焦亡相结合,可大量促进干扰素(IFN)分泌,从而形成STING–IFN介导的促免疫微环境,进一步增强NK细胞治疗。这些结果表明,在癌细胞表面锚定可激活NK细胞的靶抗原,是应对肿瘤异质性治疗挑战的一种具有转化潜力的策略。
Natural killer (NK) cell therapies, primarily based on chimeric antigen receptor NK cells (CAR-NK), have been developed and applied clinically for therapeutic treatment of patients with mid-to-late-stage tumors.
However, NK cell therapy has limited efficacy due to insufficient antigen expression on the tumor cell surface.
Here, a universal "illuminate tumor homogenization antigen properties" (ITHAP) strategy to achieve stable and controlled antigen expression on the surface of tumor cells using nanomedicine, thus significantly enhancing the immune recognizability of tumor cells, is described.
The ITHAP strategy is used to generate bio-liposomes (Pt@PL-IgG) composed of intermingled platelet membranes and liposomes with NK-activatable target antigen (IgG antibodies) and cisplatin pre-drug. It is demonstrated that Pt@PL-IgG successfully targets tumor cells using the autonomous drive of platelet membranes and achieves IgG implantation on tumor cells by utilizing membrane fusion properties.
Moreover, it is shown that the Pt-DNA complex combined with NK cell-induced pyroptosis causes substantial interferon (IFN) secretion, thus providing a synthase-stimulator of interferon genes (STING)-IFN-mediated positive immune microenvironment to further potentiate NK therapy. These results show that anchoring cancer cells with NK-activatable target antigens is a promising translational strategy for addressing therapeutic challenges in tumor heterogeneity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。